SHANGHAI – Uni-Bio Science Group Ltd. has submitted a new drug application (NDA) to the CFDA for Uni-PTH, a biosimilar of Forteo (teriparatide, Eli Lilly and Co.).
SHANGHAI – Any discussion of innovative biologics at the recent Chinabio Forum inevitably brought up biosimilars; it is difficult to have one without the other, probably because local companies of any size or staying power developing biologics take that twin strategy, filling their pipelines with biosimilars, whether me-too or bio-better, along with a smattering of novel candidates.
SHANGHAI – In its seventh year, the Chinabio Partnering Forum is the most active partnering event in China, akin to the J.P. Morgan Healthcare Conference. Even after a tough year for Western companies with corruption probes rattling the industry and regulatory hurdles inching ever higher, "big pharmas are still committed to China," said Greg Scott, founder and chairman of the Chinabio Group.
SHANGHAI – Any discussion of innovative biologics at the recent Chinabio Forum inevitably brought up biosimilars; it is difficult to have one without the other, probably because local companies of any size or staying power developing biologics take that twin strategy, filling their pipelines with biosimilars, whether me-too or bio-better, along with a smattering of novel candidates.
SHANGHAI – In its seventh year, the Chinabio Partnering Forum is the most active partnering event in China, akin to the J.P. Morgan Healthcare Conference. Even after a tough year for Western companies with corruption probes rattling the industry and regulatory hurdles inching ever higher, "Big pharmas are still committed to China," said Greg Scott, founder and chairman of the Chinabio Group in his keynote address. "Partnering activity is definitely on the rise."
SHANGHAI – Shanghai-based Ark Biosciences Inc. has received financial backing, the amount undisclosed, to usher its lead candidate through phase II trials in Australia and possibly other sites. Ark is developing AK0529, an asset licensed from Roche AG to treat respiratory syncytial virus (RSV), a significant cause of death for children younger than 5 and the elderly.
SHANGHAI – Shanghai-based Ark Biosciences Inc. has received financial backing, the amount undisclosed, to usher its lead candidate through phase II trials in Australia and possibly other sites. Ark is developing AK0529, an asset licensed from Roche AG to treat respiratory syncytial virus (RSV), a significant cause of death for children younger than 5 and the elderly.
SHANGHAI – Increasingly, Chinese biotechs are finding the time is right to take their pipelines to the U.S., and Sihuan Pharmaceutical Holdings Group Ltd., China's fourth largest pharma company (in hospital sales), is the latest to take the leap.
